Navigation Links
Sinovac Selected by Beijing CDC to Supply Hepatitis A Vaccine Healive(R)
Date:6/1/2010

BEIJING, June 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today that it has received the confirmation from the China International Tendering Company that Sinovac was selected by the Beijing Centers for Diseases Control and Prevention (Beijing CDC) to supply the Company's hepatitis A vaccine, Healive, to the Beijing Expanded Program of Immunization (EPI).

As part of the bidding process, the Beijing CDC evaluates potential suppliers and assigns scores for different factors, including product quality, service and price. Based on the comprehensive score, Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order. The total ordered quantity allocated to Sinovac is approximately 477,000 doses.

Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented, "We are very pleased to have been awarded the purchase order for our hepatitis A vaccine by the Beijing Government, as it is a testament to our core competencies as a high quality domestic vaccine manufacturer. We will leverage our manufacturing capacity and established quality controls to produce the doses pursuant to the purchase order."

In February 2008, the Chinese government included hepatitis A vaccine into its national immunization program, and announced plans to expand vaccination to newborns nationwide by the end of 2010. The EPI program covers children at 18 months of age. The purchase plan from the Beijing CDC reflects the continued expansion of government purchase programs for vaccines as it is part of the national expanded immunization program (EPI) funded by Chinese government.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), and Anflu(R) (influenza). Panflu(TM), Sinovac's pandemic influenza vaccine (H5N1), has already been approved for government stockpiling. Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines. Its 30%-owned joint venture, Sinovac Dalian, focuses on the research, development, manufacturing and commercialization of vaccines, such as rabies, chickenpox, mumps and rubella vaccines for human use.

    For more information, please contact:

    Sinovac Biotech Ltd.:
     Chris Lee
     Tel:   +86-10-8279-9659
     Fax:   +86-10-6296-6910
     Email: info@sinovac.com

    Investors:
     Amy Glynn/Stephanie Carrington
     The Ruth Group
     Tel:   +1-646-536-7023/7017
     Email: aglynn@theruthgroup.com
            scarrington@theruthgroup.com

    Media:
     Jason Rando
     The Ruth Group
     Tel:   +1-646-536-7025
     Email: jrando@theruthgroup.com


'/>"/>
SOURCE Sinovac Biotech Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Sinovac Announces Plan to Launch Offering of Common Shares
2. Sinovac Announces Recent Developments
3. Sinovac Obtains Fifth H1N1 Vaccine Order from Chinese Central Government
4. Sinovac Named One of Chinas Top 10 Most Competitive Companies Listed Overseas in 2009
5. Sinovacs CEO Weidong Yin Nominated for China Central Televisions Prestigious Economic Man-of-the-Year Award
6. Sinovac Obtains Fourth H1N1 Vaccine Order from Chinese Central Government
7. Sinovac Files Shelf Registration Statement
8. Sinovacs PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population
9. Sinovac Receives Purchase Order from Shanghai Government to Supply Hepatitis A Vaccine Healive(R)
10. Sinovac Initiates Phase II Volunteer Enrollment for Split Viron Pandemic Influenza (H5N1) Vaccine
11. Sinovac Provides Update in Pandemic Influenza Vaccines (H5N1) Phase II Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017 Elysium Health ... Cambridge academic scientists ... The Milner Therapeutics Institute today announces Elysium Health ... has committed significant investment for collaborative projects with academic researchers ... years. This is the first major research investment outside the ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
(Date:3/27/2017)... March 27, 2017 LightIntegra Technology Inc. today ... "Bill" Dubiel as President and Chief Executive Officer effective ... the Board of Directors of LightIntegra. Paul Geyer ... of LightIntegra. "This is the perfect ... Chief Executive Officer. We,ve selected a very strong leader ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... The Executives, Staff & Clients of MGE: Management Experts ... for Tots Literacy Campaign at their Semi-Annual Graduation and Fundraiser Event at MGE’s St. ... ranks at number 14 internationally in literacy. Statistically, a direct relation can be a ...
(Date:3/28/2017)... ... 2017 , ... Public relations pros work hard to earn placements and ... While many results are clear, much of PR is hard to quantify. Goal-setting and ... to measurement, firms should always take an all-inclusive approach that takes both traditional and ...
(Date:3/28/2017)... ... March 28, 2017 , ... Thank you to all who ... 8-10. , This event was exclusive to providers and offered an opportunity to ... took place at the Manchester Grand Hyatt where attendees gathered for a lively discussion ...
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... patients for clear braces. People who want straight teeth without the extensive time ... in Clearwater, FL, without acquiring a referral. A custom-designed series of virtually ...
(Date:3/27/2017)... ... March 27, 2017 , ... This is the ... popHealth Community in 2014. It is the culmination of collaborative efforts by ... Project Group. OSEHRA Organizational Member Zato Health co-funded the ONC certification and provided ...
Breaking Medicine News(10 mins):